CLINICAL ROLE -
How Many Americans with High Cholesterol Could be Eligible for PCSK9 Inhibitors?
Specialty drug costs for 13 to 23 million patients in the United States would be $185 to 342 billion.
Rational Drug Prescribing Could Save Up to $1 Billion
Model predicts millions of dollars can be saved just by avoiding 3 high-cost, low-reward drugs.
Indication-Specific Pricing: Challenges in the US Context
Are the unmeasured, potential benefits of indication-specific pricing worth the complication and risk?
All Oral Regimen Could be Future of Multiple Myeloma Treatment
Approval of first oral proteasome inhibitor, ixazomib (Ninlato), may ease treatment burden for multiple myeloma.
All-Oral Regimens: Possible New Standard for Advanced Multiple Myeloma
A new pill makes all-oral therapy possible for patients with multiple myeloma.
Biosimilars Will Drive Changes in the Pharmaceutical Market by 2020
Policy decisions will affect how much biosimilars improve patient access to advanced treatments.
Are Americans Ready for Couples' HIV Counseling?
Study shows what couples with at least 1 HIV-positive partner want to get most out of HIV counseling, which can promote health services and treatment.
Monitoring Infants for Hepatitis C Virus
One clinic found little value in the early testing of infants born to HCV-infected mothers.
National Health Insurance the Only Sustainable Option for the United States
Finance reform is the biggest unresolved problem plaguing the US healthcare system.
How Safe are New HCV Treatments for Liver Transplant Patients?
Is sofosbuvir plus ribavirin a viable option for hepatitis C virus therapy after liver transplant?
Pharmaceutical Market Predictions for the United States and China
Pricing and outcomes will be competitive factors in the 2 largest national drug markets into 2020.
Can a Racial Divide Explain Non-Treatment of HCV among the HIV-HCV Coinfected?
Study finds a common assortment of reasons for non-initiation of hepatitis C therapy, regardless of patient race or ethnicity.
Nonelderly Disabled Still Face Significant Medicare Prescription Cost Barriers
Disabled Medicare beneficiaries, especially those with multiple comorbidities, struggle to afford their prescriptions.
Prescription Cost Barriers Persist for Nonelderly Disabled Under Part D
Disabled Medicare beneficiaries, especially those with many comorbidities, continue to struggle to afford prescriptions.
Legislative Threats to Maximum Allowable Cost Programs
Special interest legislation could inflate generic drug prices.
Pharmacy Benefit Management Tools Could Save Billions Over the Next Decade
Using PBM tools at current levels can save payers $654 billion over the next 10 years.
Mobile Apps May Reduce Hospital Readmission in Specialty Pharmacy Patients
Nonmedical workers and mobile technology can play a pivotal role in risk prediction.
No Prescription Impact from a Switch to Global Budgeting
Combined with a pay-for-performance program, global budgets put provider organizations at risk of incurring medical expenses above a predetermined amount.
Low Health Literacy Associated with Healthcare Utilization and Spending
Study finds patient health literacy inversely associated with healthcare utilization and costs, especially for prescriptions.
Deciphering Pharmaceutical Information in Social Media
Study examines how pharmaceutical companies use social media to market products and interact with the public.
How Accurate is Pharmaceutical Information Spread on Social Media?
Illegal ads and unmoderated drug reviews potentially mislead social media users.
Could Universal Prescription Drug Coverage Lower Healthcare Costs?
Study estimates the private sector could save much more than the public sector would spend.
Healthcare Cost-Effectiveness for a Population, Not Just One Patient
A new decision-making tool aims to make effective treatments available to more patients within a set budget.
Pilot Anti-Fraud Prior Authorization Requirements Loom for Health Agencies
A pilot demonstration will measure the extent of probable fraud in the home health industry
New Prior Authorization Requirements are Coming for Home Health Agencies
An anti-fraud pilot demonstration is planned for home health agencies in several states.
Review of Incentive-Based Drug Benefit Designs
Differential pricing influences drug use, but more research is needed to assess its value and health outcomes.
Mixed Results from Tightening Formulary Restrictions
Tighter restrictions led to discontinuation, adherence, generic use, and cost reduction.
What Influences Pharmacies to Dispense Payer Preferred Drugs?
Study finds dispensing behavior to be largely compliant with payers, especially in competitive regions.
Promising Treatment Outcomes in Elderly Patients With Multiple Myeloma
Combination therapy with lenalidomide and dexamethasone plus bortezomib in multiple myeloma patients shows significant improvement.
Positive Outcomes in Novel Treatments for Elderly Patients with Multiple Myeloma
A study found positive outcomes of dose-attenuated combination therapy with lenalidomide and dexamethasone plus bortezomib in multiple myeloma patients.
2 Clarke Drive Cranbury, NJ 08512